NCT04667910View on ClinicalTrials.gov

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

November 16, 2022

Study Completion Date

November 16, 2022

Conditions
Central Retinal Vein Occlusion
Interventions
DRUG

601 1.25mg

Solution for injection (intravitreal use)

DRUG

Ranibizuman 0.5 mg

Solution for injection (intravitreal use)

Trial Locations (1)

300384

TianJing Medical University Eye Hospital, Tianjing

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT04667910 - 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) | Biotech Hunter | Biotech Hunter